+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4591925
  • Report
  • 114 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • Biogen Inc
  • Diagenic ASA
  • Eisai Co. Ltd
  • Eli Lilly & Company
  • F. Hoffmann-La Roche
  • GE Healthcare
  • MORE
Market Overview

The global Alzheimer’s disease diagnostics and therapeutics market was valued at USD 7,537.4 million in 2018, and is estimated to be valued at USD 11,138.2 million in 2024, witnessing a CAGR of 6.7%. The key factors propelling the growth of this market are investment in biomarkers for drug development, increasing pipeline drug development, increasing sophisticated diagnostics for early detection, along with more precise drug development, and emerging novel diagnostics technologies.

Alzheimer’s disease is one of the most prevalent types of dementia that occurs worldwide. According to the Alzheimer’s disease facts and figures, it is estimated that in every 33 seconds, a new case of Alzheimer's disease occurs, leading to high prevalence of the disease, of almost 35 million patients, around the world. The development of clinical diagnostics and therapeutics for Alzheimer's disease (AD) and other neurodegenerative conditions is becoming very important. In about 10-15% cases, the clinical diagnosis of AD is inaccurate. So, certain biomarkers that may improve the accuracy of the diagnosis are used. Biomarkers are neurochemical indicators used to determine the risk or prevalence of the disease.

Investing in biomarkers for drug development and early detection of AD acts as a major driver, and fuels the growth of the Alzheimer's disease diagnostics and therapeutics market, globally.

Scope of the Report

As per the scope of the report, Alzheimer's disease (AD) is a progressive, degenerative disorder that attacks the brain's nerve cells or neurons, resulting in loss of memory, thinking and language skills, and behavioural changes.

Key Market Trends

Cholinesterase Inhibitors are Expected to hold the Highest Market Share in the Therapeutics Segment

In the therapeutics segment of the Alzheimer’s disease diagnostics and therapeutics market. Cholinesterase inhibitors are believed to have the largest market size and are expected to witness a CAGR of 6.4% during the forecast period.

Cholinesterase inhibitors are used for the treatment of Alzheimer’s. These cholinesterase inhibitors are approved by the US FDA. Most physicians and perhaps most patients consider cholinergic drugs. Donepezil, galantamine, and rivastigmine are the generic names of cholinesterase inhibitors, which are likely to be the first-line pharmacotherapy choice for mild to moderate Alzheimer’s disease. These drugs have somewhat different pharmacological properties, but all of them work by the same mechanism, which involves inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.

The market is dominated by leading brands, such as Aricept, Exelon, and Reminyl; Aricept, whose active ingredient is a cholinesterase inhibitor, holds the largest market share. Several clinical trials are ongoing on cholinesterase inhibitors to increase drug efficacy and decrease adverse effects. Hence, oeing to the developments, the cholinesterase inhibitor drugs market is expected to grow during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America currently dominates the market for Alzheimer’s disease diagnostics and therapeutics ,and is expected to continue its stronghold for a few more years. The United States holds the largest share of the global Alzheimer’s disease diagnostics and therapeutics market. According to the Alzheimer’s Association, more than 5 million Americans suffer from Alzheimer’s, as of 2017. The United States is considered to be the global leader in Alzheimer’s disease intervention and management. America has a large pool of biopharmaceutical companies, which cumulatively have 85 drugs for combating Alzheimer’s disease in various stages of the pipeline. Hence, the market is expected to register a healthy CAGR over the forecast period.

Competitive Landscape

The Alzheimer’s disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are increasing their market presence, by introducing new technologies with better results. Companies, like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily & Co., hold a substantial market share in the Alzheimer’s disease diagnostics and therapeutics market.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogen Inc
  • Diagenic ASA
  • Eisai Co. Ltd
  • Eli Lilly & Company
  • F. Hoffmann-La Roche
  • GE Healthcare
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Investment in Biomarkers for Drug Development
4.2.2 Increasing Pipeline Drug Development
4.2.3 Increasing Sophisticated Diagnostics for Early Detection and More Precise Drug Development
4.2.4 Emerging Novel Diagnostic Technologies
4.3 Market Restraints
4.3.1 Early Diagnosis of the Indication is Challenging
4.3.2 Decline in the Market Due to Failures of Late-stage Drugs
4.3.3 Lack of Surrogate Markers for Drug Discovery and Drug Development
4.3.4 Insufficient Research Funding and Lengthy, Expensive, and Uncertain Process
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Therapeutics
5.1.1 Cholinesterase Inhibitors
5.1.2 NMDA Receptor Antagonists
5.1.3 Other Therapeutics
5.2 By Diagnostics
5.2.1 Brain Imaging
5.2.2 CFS Test for Alzheimer's Disease
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche
6.1.2 Novartis AG
6.1.3 Merck & Co. Inc
6.1.4 Pfizer Inc
6.1.5 Eisai Co. Ltd
6.1.6 Biogen Inc
6.1.7 Johnson & Johnson
6.1.8 Eli Lilly & Company
6.1.9 Amarantus Bioscience Holdings Inc
6.1.10 Diagenic ASA
6.1.11 Navidea Biopharmaceuticals
6.1.12 GE Healthcare

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • F. Hoffmann-La Roche
  • Novartis AG
  • Merck & Co. Inc
  • Pfizer Inc
  • Eisai Co. Ltd
  • Biogen Inc
  • Johnson & Johnson
  • Eli Lilly & Company
  • Amarantus Bioscience Holdings Inc
  • Diagenic ASA
  • Navidea Biopharmaceuticals
  • GE Healthcare
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4591925
Adroll
adroll